[1] |
XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu.
Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652.
|
[2] |
BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong.
Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
|
[3] |
LI Chenhao, YU Xihua, YAN Wenhao, CHAI Yuxia, LI Yanyan, LI Kun, LI Zeyun.
Research progress on the relationship between pediatric epilepsy and vitamin D
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1299-1306.
|
[4] |
LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong.
Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
|
[5] |
ZHANG Quan, SHI Shiyuan, HAN Guihe.
1,25 dihydroxy vitamin D3 for immunoregulation in the treatment of spinal tuberculosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 787-793.
|
[6] |
ZHENG Lichun, WANG Xiang, WANG Wenmei.
Management strategies and suggestions on stomatological clinical trials under the influence of epidemic
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 213-216.
|
[7] |
YU Tianyi, JIAO Guangyang, HUANG Doudou, CHEN Yong, XU Deduo, QIU Shi, CHEN Wansheng, ZHANG Feng, WANG Bolong.
Analysis of the effective components and mechanism of Yufang Fangji II for prevention of COVID-19 based on UHPLC-Q-TOF/MS and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1127-1145.
|
[8] |
YIN Yujie, CHANG Liping.
Pharmacological research and clinical applications progress of Lianhua Qingwen capsules/granules in respiratory diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1174-1180.
|
[9] |
XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa.
Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
|
[10] |
MU Xin, ZHAO Ying, ZHANG Lan, CUI Yimin, ZHANG Yongxiang, DU Guanhua.
Drug clinical trial of COVID-19 in China: A brief analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 869-877.
|
[11] |
HAO Yuqi, XIAO Yao, WANG Qian, JIANG Xingxu.
Therapeutic drugs and treatment of SARS-CoV-2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 716-720.
|
[12] |
ZHANG Zhengfu, LI Meng, WANG Jianan.
Protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 421-425.
|
[13] |
QIN Qun, LIU Xiaobao, YANG Guoping, LI Zhuo, LI Kunyan, HUANG Zhijun, LIU Zhaoqian.
COVID-19:Emergency response measures for GCP in Hunan province under the first level response of major public health emergencies(2.0 Version)
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 323-328.
|
[14] |
LIU Qi, XIA Shuai, JIANG Shibo.
Research and development of antiviral drugs against new coronavirus 2019-nCoV
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 241-245.
|
[15] |
XIANG Yuxia, ZENG Chan, HUANG Zhijun, WANG Xiaomin, ZHANG Zeyu, YANG Guoping.
Analysis of clinical trial registration information of COVID-19 in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 135-140.
|